GlassScriptPhysician profile
Duilio E Valdivia
NPI 1609805217
$1,103.45
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $945 · 2020: $159.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $225.52 | 2019 | |
| Janssen Biotech, INC. | $207.94 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $170.91 | 2019 | |
| Pfizer INC. | $91.30 | 2019-2020 | |
| Celgene Corporation | $90.15 | 2019 | |
| Rigel Pharmaceuticals, INC. | $82.27 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $62.11 | 2019 | |
| Incyte Corporation | $31.77 | 2019-2020 | |
| Daiichi Sankyo INC. | $19.54 | 2019 | |
| Astellas Pharma US INC | $16.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.71 | 2019 | |
| Glaxosmithkline, LLC. | $12.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duilio Valdivia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.